Allogene Therapeutics (NASDAQ:ALLO) initiated with Buy rating and $36 (24% upside) price target at Canaccord Genuity.
BioNTech (NASDAQ:BNTX) initiated with Buy rating and $21 (27% upside) price target at BofA Merrill Lynch, Buy rating and $22 target at Canaccord, Buy rating and $20 target at Kempen & Company, Buy rating and $21 target at UBS, Outperform and $20 target at SVB Leerink and Overweight rating and $23 target at JPMorgan. Shares up 2% premarket.
TCR2 Therapeutics (NASDAQ:TCRR) initiated with Buy rating and $19 (37% upside) price target at H.C. Wainwright.
Bluebird bio (NASDAQ:BLUE) upgraded to Outperform with a $124 (50% upside) price target at Wedbush. Shares up 3% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.